J Clin Pathways. 2018;4(2):12-16.
ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors
The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for High-Quality Clinical Pathways.
ICER Report Shows Cost of CAR-T Therapies Align With Clinical Benefit
FDA-approved CAR T-cell therapies may be associated with high costs, but the therapies are priced in alignment with their clinical value.
Real-World Health Care Utilization, Costs of Pulmonary Arterial Hypertension
A recent study evaluated health care utilization and costs of pulmonary arterial hypertension in a real-world setting by comparing periods before and after treatment initiation.
ASCO, NCCN Release Clinical Guidelines for Managing Immunotherapy-Related Toxicities
The American Society of Clinical Oncology and the National Comprehensive Cancer Network have collaborated for the first time to release new clinical guidelines for managing immunotherapy-related toxicities.
Socioeconomic Deprivation, Lower Hospital Treatment Volume Linked With Poor Survival in ALL
Survival outcomes may be worse for patients with ALL living in intermediate and high socioeconomically deprived areas as well as for those treated in hospitals with lower volumes of patients.
Routine Use of Palliative Care Underutilized in Ovarian Cancer
A study found that palliative care for patients with ovarian cancer was often provided later than recommended in national guidelines.
Cost of Chemotherapy Administration Higher in Outpatient Setting Than in Physician Office
Commercial payers are spending almost twice as much on chemotherapy administered in hospital outpatient departments compared with therapy administered in physician offices.
Racial Disparities in Gastric Cancer Preoperative Chemotherapy Use
A National Cancer Database analysis revealed racial and ethnic disparities in patients with gastric cancer in the use of preoperative chemotherapy and in outcomes.